EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

DEVELOPMENT AND EVALUATION OF MUCOADHESIVE FLUNARIZINE NANOEMULSION FOR NOSE-TO-BRAIN DRUG DELIVERY IN THE MANAGEMENT OF ALZHEIMER’S DISEASE

Mudrika K, Venkata Badarinath A

Journal of Innovations in Applied Pharmaceutical Science (JIAPS) · 20.03.2026 · 22-26

DOI: 10.37022/jiaps.v11i1.816 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Innovations in Applied Pharmaceutical Science (JIAPS), online erschienen am 20.03.2026. Verfasst von Mudrika K und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease is a progressive neurodegenerative disorder characterised by memory loss and cognitive impairment. The delivery of therapeutic agents to the brain is significantly restricted by the blood–brain barrier (BBB), limiting drug effectiveness. Flunarizine, a lipophilic calcium channel blocker, exhibits potential neuroprotective activity; however, its oral bioavailability is limited due to extensive first-pass metabolism. The present study aimed to develop and evaluate a mucoadhesive nanoemulsion of Flunarizine for intranasal (nose-to-brain) drug delivery to enhance brain targeting and therapeutic efficacy. Nanoemulsions were formulated using sesame oil as the oil phase, Tween 80 as the surfactant, PEG 400 as the co-surfactant, and distilled water as the aqueous phase, employing the vortexing–sonication method. A total of nine formulations (F1–F9) were developed using an L9 Taguchi orthogonal array design. The prepared formulations were evaluated for physicochemical parameters such as pH, drug content, entrapment efficiency, particle size, polydispersity index, zeta potential, and in-vitro drug diffusion.Among the formulations, F3 demonstrated optimal characteristics, including suitable particle size, high entrapment efficiency, stability, and enhanced drug release. Drug release kinetics indicated that the optimised formulation followed zero-order kinetics with a diffusion-controlled release mechanism. The findings suggest that the developed mucoadhesive Flunarizine nanoemulsion is a promising approach for intranasal drug delivery, offering improved brain targeting and therapeutic potential in the management of Alzheimer’s disease.

Zitieren

APA

K, M., & A, V. B. (2026). DEVELOPMENT AND EVALUATION OF MUCOADHESIVE FLUNARIZINE NANOEMULSION FOR NOSE-TO-BRAIN DRUG DELIVERY IN THE MANAGEMENT OF ALZHEIMER’S DISEASE. Journal of Innovations in Applied Pharmaceutical Science (JIAPS), 22-26. https://doi.org/10.37022/jiaps.v11i1.816

Vancouver

K M, A VB. DEVELOPMENT AND EVALUATION OF MUCOADHESIVE FLUNARIZINE NANOEMULSION FOR NOSE-TO-BRAIN DRUG DELIVERY IN THE MANAGEMENT OF ALZHEIMER’S DISEASE. Journal of Innovations in Applied Pharmaceutical Science (JIAPS). 2026:22-26. doi:10.37022/jiaps.v11i1.816

BibTeX
@article{K2026,
  author = {K, Mudrika and A, Venkata Badarinath},
  title = {DEVELOPMENT AND EVALUATION OF MUCOADHESIVE FLUNARIZINE NANOEMULSION FOR NOSE-TO-BRAIN DRUG DELIVERY IN THE MANAGEMENT OF ALZHEIMER’S DISEASE},
  journal = {Journal of Innovations in Applied Pharmaceutical Science (JIAPS)},
  year = {2026},
  pages = {22--26},
  doi = {10.37022/jiaps.v11i1.816}
}
Kostenlos starten →